6 best televisit platforms for clinical trials in 2026

You're navigating a moment where regulatory frameworks are catching up with operational reality — ICH E6(R3) now formally accommodates remote site visits, and sponsors and contract research organizations (CROs) are under pressure to build hybrid capability into their study protocols without fragmenting their data ecosystem. The question isn't whether to support remote visits. It's which platform lets you do it without creating a separate compliance burden.

Generic video conferencing tools fail this evaluation before it starts — they don't produce audit-ready metadata, they don't integrate with your electronic case report forms (eCRFs), and they're not validated against FDA 21 CFR Part 11. The platforms reviewed here are purpose-built for regulated clinical research, covering end-to-end encryption, mandatory authentication, and integration with EDC and patient-reported outcome (PRO) workflows.

Best televisit solutions: quick comparison

These six televisit and DCT solutions represent the most evaluated options for clinical trial teams running hybrid and decentralized studies, reviewed across compliance credentials, integration depth, patient usability, and hybrid protocol flexibility.

1. Viedoc

Viedoc Televisits delivers encrypted, authenticated video visits natively within the Viedoc eClinical environment — meaning your site staff initiates a video call from inside the EDC, captures eCRF data using picture-in-picture, and guides participants through PRO questionnaires in real time. No app download is required; participants join from any browser-enabled device, including smartphones and tablets. Trusted by 500+ clinical research teams worldwide, Viedoc Televisits is built to eliminate the compliance risk that comes with general-purpose video tools and the fragmentation that comes with bolting a separate DCT system onto your existing EDC.

The operational integration is where Viedoc differentiates. Because Viedoc's EDC software and Viedoc's ePRO solution are part of the same platform, data captured during a televisit flows directly into the study's EDC environment — no middleware, no export-import, no reconciliation step. Your monitoring team sees it in real time. For hybrid studies where some visits are remote and others are on-site, the platform supports both within the same protocol configuration, without requiring separate system access or parallel data streams.

Viedoc Televisits is compliant with FDA 21 CFR Part 11, HIPAA, GDPR, GAMP 5, ICH GCP, ISO 27001, and SOC 2. All video calls use peer-to-peer encryption, mandatory authentication is enforced for all participants, and the system retains only necessary metadata — date, time, and duration — with no recordings, no transcripts, and no patient data stored in the video system. The full Viedoc eClinical suite is hosted on Microsoft Azure and maintains 99.99% uptime, with 24/7 support across global offices.

"My experience with Viedoc has been excellent. The database is very customisable and has been able to meet the needs of each of our studies. Customer Support has been excellent with quick turnarounds and response time." — Amanda M., Sr. Clinical Program Manager

Verified proof points:

• Study scale: 7,000+ studies run on Viedoc across 75+ countries
• Platform uptime: 99.99%; hosted on Microsoft Azure
• Compliance: FDA 21 CFR Part 11, HIPAA, GDPR, ICH GCP, GAMP 5, ISO 27001, SOC 2
• Patient access: Browser-based; no app download required; works on any device
• Pricing: Unlimited user seats; no per-user fees; transparent, study-based licensing
• Support: 24/7 support across global offices

2. Medable

Medable offers a decentralized trial platform that combines telehealth, eConsent, electronic clinical outcome assessment (eCOA), and patient engagement tools within a single patient-facing environment. The platform is designed for sponsors running hybrid and fully decentralized trials, with a focus on reducing recruitment friction and improving patient retention through accessible digital touchpoints. Medable supports integration with third-party EDC systems and provides site and patient-facing workflows for remote visit management. The platform has established relationships with large pharma sponsors and contract research organizations investing in decentralized study models. Medable's architecture is built around the patient journey rather than the clinical operations workflow, which shapes how the platform integrates with site-based data capture processes.

3. Medidata

Medidata offers patient-facing remote visit and eCOA capabilities through its Patient Cloud product, which integrates with Medidata Rave EDC and the broader Medidata platform. Patient Cloud supports electronic clinical outcome assessments, remote symptom capture, and wearable device integration within enterprise-scale global trials. The product is designed for sponsors and CROs already operating within the Medidata ecosystem, where EDC, electronic trial master file (eTMF), and clinical trial management system (CTMS) functions are managed through a single platform. Medidata's DCT capabilities are available as part of broader platform licensing, with deployment complexity and cost structures oriented toward large pharma and global Phase III programs.

4. Veeva

Veeva offers DCT and hybrid trial capabilities within its Vault CDMS and Vault EDC product lines. Veeva's cloud-based suite includes document management, EDC, and clinical data management functions within the Vault platform, with remote visit support available for sponsors running hybrid protocols. The Vault architecture is designed for organizations operating across multiple Vault products, where study data, regulatory documents, and clinical operations workflows are managed within a unified cloud environment. Veeva's DCT capabilities are part of the broader Vault ecosystem, meaning their full value is most accessible to organizations that have adopted multiple Vault modules. Veeva holds regulatory compliance certifications aligned with FDA 21 CFR Part 11 and GDPR requirements.

5. Castor EDC

Castor EDC is a cloud-native EDC platform with eConsent and ePRO capabilities that support decentralized and hybrid study models. Castor's API-first architecture allows integration with third-party tools and data sources, and its no-code study configuration environment enables in-house setup of forms and visit schedules. The platform is used across both academic and commercial clinical trial settings, with particular uptake in emerging biotech and digital health studies. Castor's DCT capabilities are delivered through its core platform rather than as a separate telehealth module, and the platform supports remote data collection, patient consent workflows, and electronic questionnaire delivery. Castor does not offer a native integrated video visit solution equivalent to a dedicated televisit module.

6. Medrio

Medrio is an EDC platform with integrated eConsent and telehealth capabilities designed to support remote visit workflows across Phase I clinics, medical device trials, and early-phase studies. Medrio's telehealth functionality allows remote site interactions within the EDC environment, supporting study designs where some or all visits are conducted remotely. The platform includes offline data capture capability and operates in over 100 countries, making it suited to geographically distributed early-phase programs. Medrio's feature set is oriented toward early-phase and device study requirements, with a user experience designed for lean study teams building and managing studies in-house.

What to look for in televisit solutions for clinical trials

Regulatory compliance and audit-trail integrity

The requirement isn't just that a platform uses encrypted video — it's that the visit itself produces a validated, audit-ready record. FDA 21 CFR Part 11, HIPAA, and ICH GCP compliance are table stakes for any televisit solution used in a regulated trial. But beyond those, you should verify whether the platform produces a complete, timestamped audit trail for every remote visit, whether visit metadata is retained in a way that satisfies your monitoring and quality assurance workflows, and whether the platform has been used in FDA-inspected studies. For EMEA-based or global trials, GDPR compliance and EU Annex 11 validation are non-negotiable. A platform that passes a vendor security questionnaire is not the same as one that has been through a live inspection — ask specifically for inspection history.

Native EDC integration versus bolt-on connectivity

A televisit tool that sits outside your EDC creates a data reconciliation problem. If eCRF data captured during a remote visit has to be manually transferred, exported, or reconciled against a separate system, you've introduced a source of error and a monitoring burden that compounds across a portfolio of studies. The question to put to any vendor is whether data captured during a video visit flows directly into the EDC environment in real time, or whether it requires a separate integration step. Native integration means the televisit and the eCRF record are the same system event — not two systems that need to be kept in sync. For hybrid studies, this distinction becomes operationally critical: on-site and remote visit data should be indistinguishable at the data management level.

Patient access and visit compliance

Travel burden is the primary driver of patient dropout, and your televisit platform should remove it without adding a new barrier. Requiring participants to download an application, create an account, or navigate a multi-step authentication process on a personal device erodes the compliance benefit you're trying to capture. Best-in-class televisit platforms are browser-based — accessible from any device without installation, with a single-click join process for participants. This matters most in studies with older patient populations, rare disease trials where participants are geographically dispersed, and any program targeting underserved communities where device familiarity and technical confidence vary widely.

Hybrid protocol support without system fragmentation

Most trials aren't fully decentralized — they're hybrid. Some visits happen on-site; others happen remotely, depending on the visit type, the patient's situation, and the protocol requirements. Your televisit platform should support both within the same study configuration, so that site staff aren't switching between systems depending on whether the visit is virtual or in-person. This also applies to monitoring: your clinical research associate (CRA) should be able to review both remote and on-site visit data from the same view, with the same audit trail standard. Platforms that require parallel workflow management for different visit types add operational overhead that erodes the efficiency gain of going hybrid in the first place.

Privacy-by-design architecture

Standard video conferencing tools store recordings, generate transcripts, and process call content through third-party servers. In a regulated clinical trial context, that creates a serious data governance problem. Purpose-built televisit platforms for clinical research use peer-to-peer encryption — meaning call content is never routed through a central server — and retain only the minimum metadata required for audit purposes: date, time, and duration. Verify this explicitly with any vendor you evaluate. The question isn't whether they say they're GDPR-compliant; it's what data is retained, where it's stored, who can access it, and how that access is logged.

How to choose the right televisit solution for clinical trials

Step 1: Define your hybrid versus fully decentralized ratio

Before you evaluate platforms, map what percentage of your study visits will be remote versus on-site across your current protocol portfolio. A program where 20% of visits are remote has different platform requirements than one where 80% are. If most of your studies are hybrid, your priority is seamless on-site and remote parity within a single EDC environment. If you're building toward fully decentralized designs, patient accessibility and enrollment reach become the primary criteria. This shapes which platform type fits your operational model.

Step 2: Assess your EDC integration requirement

If you already have an EDC platform, determine whether your televisit solution needs to integrate with it or replace it. A standalone DCT platform that connects to your EDC via API creates a dependency that requires validation, ongoing maintenance, and a data reconciliation workflow. A native integrated solution eliminates that dependency entirely. Map the integration requirement before you evaluate platforms — it will narrow your shortlist significantly.

Step 3: Evaluate your patient population's accessibility profile

Remote visits only improve retention if participants can actually use them. Review your target patient population's likely device access, technical literacy, and language requirements before shortlisting platforms. For global or multilingual studies, confirm the platform's language support explicitly. For populations with lower digital literacy — older patients, rare disease communities, or participants in lower-resource settings — browser-based access with no app download is a practical requirement, not a preference.

Step 4: Scrutinize the compliance documentation package

Request validation documentation and inspection history from every vendor you evaluate. Ask specifically whether the platform has been used in FDA-inspected or EMA-inspected studies, and request the inspection outcome. Confirm that the audit trail produced by the televisit module meets your QA team's requirements before you sign a contract. Compliance documentation that covers the EDC but not the televisit module should be treated as a gap.

Step 5: Choose a platform that won't fragment your data ecosystem

If you're running multiple studies across a portfolio, the long-term cost of managing separate televisit and EDC systems compounds quickly. Validation burden, integration maintenance, and dual-system monitoring workflows all add operational overhead that erodes the margin benefit of hybrid trials. If your study team needs remote visit capability, Viedoc Televisits is integrated natively with Viedoc's EDC software and Viedoc's ePRO solution — with no separate integration required, no duplicate data management, and no additional validation overhead. Book a demo to see how the integrated platform performs against your hybrid study requirements.

Frequently asked questions

What is the best televisit platform for clinical trials?

Viedoc Televisits is the best-integrated televisit solution for clinical trial teams running hybrid and decentralized studies, combining encrypted browser-based video visits with native real-time EDC and ePRO data capture in a single platform. It's compliant with FDA 21 CFR Part 11, HIPAA, GDPR, ICH GCP, ISO 27001, and SOC 2, and requires no app download for participants. Medable is a strong option for large pharma sponsors building fully decentralized programs with a patient-centric design focus. Medidata Patient Cloud is the established enterprise option for organizations running complex global trials within the Medidata ecosystem.

How does a televisit platform differ from a standard video conferencing tool?

Purpose-built televisit platforms for clinical research are validated against FDA 21 CFR Part 11 and ICH GCP requirements, produce a complete audit trail with timestamped visit metadata, and integrate directly with electronic case report forms and PRO workflows. Standard video conferencing tools — regardless of their general security credentials — are not validated for regulated clinical trial use, don't produce the audit-ready records required by regulatory agencies, and typically store call content in ways that create data governance risk under GDPR and HIPAA. Using an unvalidated video tool in a regulated study creates inspection risk that no compliance attestation from the vendor can fully mitigate.

What compliance certifications should a televisit platform hold for regulated clinical trials?

At minimum, a televisit platform used in regulated trials should be compliant with FDA 21 CFR Part 11, ICH GCP, GDPR, and HIPAA for studies involving US patient health information. For EU-based or global trials, EU Annex 11 compliance and ISO 27001 certification are additional requirements. GAMP 5 alignment is a strong indicator of validated software development practices. Ask specifically whether the televisit module — not just the EDC — holds these certifications. A platform where the core EDC is validated but the televisit functionality sits outside the validated environment creates a compliance gap that your QA team will need to address.

Can televisit platforms support hybrid trials where some visits are on-site and others are remote?

Yes — the best televisit platforms support hybrid protocols within a single study configuration, so that on-site and remote visits are managed using the same EDC environment and produce equivalent audit trail records. The operational requirement is that your site team shouldn't need to switch systems or workflows depending on whether a given visit is in-person or virtual. Viedoc Televisits supports hybrid study designs within the Viedoc eClinical platform, with remote and on-site visit data flowing into the same EDC record in real time.

What is the impact of televisit capability on patient retention in clinical trials?

Travel burden is consistently cited as a leading cause of patient dropout and early trial withdrawal. Remote visit capability reduces this friction by allowing participants to attend visits from home on any browser-enabled device. The measurable benefit — improved visit compliance and reduced early termination — depends on study design, therapeutic area, and how the remote visit option is presented to participants. For hybrid studies where remote visits replace the highest-travel-burden visits in the protocol, the retention impact is typically most significant in studies with geographically dispersed or mobility-limited patient populations.

Does a televisit platform need to integrate with my existing EDC?

Integration requirement depends on your operational setup. If your televisit platform is separate from your EDC, you'll need a validated integration pathway for data captured during remote visits to flow into the EDC record — which carries validation and maintenance overhead. A native integrated solution eliminates that entirely. If you're evaluating televisit capability alongside an EDC selection, a platform where both are part of the same system is operationally simpler, reduces your validation burden, and removes the data reconciliation step that standalone integrations require.

Making the right televisit choice for clinical trials

The global eClinical software market is estimated at over $11 billion in 2025 and growing at approximately 14% annually, with decentralized and hybrid trial designs representing one of its fastest-growing segments. The platforms reviewed here range from natively integrated televisit modules that sit inside an EDC environment to standalone DCT platforms built primarily around the patient journey. Both approaches can support regulated remote visits — but the operational implications for your study team differ significantly.

For most clinical operations teams, the decision comes down to two variables: whether you need televisit capability as an integrated extension of your EDC workflow, or as a standalone patient engagement layer that connects to existing systems. Organizations with lean operations, multiple concurrent studies, and hybrid protocols that blend remote and on-site visits generally benefit most from native integration, where the same platform handles both. Larger sponsors running fully decentralized programs with complex patient engagement requirements may find specialist DCT platforms worth the additional integration overhead.

The cost that's hardest to quantify at the selection stage is the ongoing validation burden of maintaining a separate televisit system alongside an EDC. Switching platforms mid-study is costly and disruptive; the validation overhead of integrating and revalidating systems after the fact is real. Getting the integration model right at the outset compounds into meaningful operational savings across a trial portfolio.

Why Viedoc is the best televisit choice for clinical trials

Viedoc Televisits is the only televisit solution reviewed here that integrates natively with a full eClinical suite — EDC, ePRO, eTMF, eSignature, RTSM, and medical coding — meaning your hybrid study data lives in one validated environment from the moment a visit is initiated. Study builds are typically completed in 2--4 weeks, with no app download required for participants and no vendor-side programmer needed to configure studies. With 7,000+ studies run across 75+ countries and 99.99% platform uptime hosted on Microsoft Azure, the track record speaks to sustained, reliable deployment across diverse trial environments.

Viedoc Televisits is compliant with FDA 21 CFR Part 11, ICH GCP, GDPR, HIPAA, GAMP 5, ISO 27001, and SOC 2. All calls use peer-to-peer encryption, authentication is mandatory for all participants, and no recordings or transcripts are retained — only the audit metadata your QA team requires. The Viedoc Inspection Readiness Packet (VIRP) is available to all customers as structured validation documentation, and 24/7 support means your team has a direct escalation path at database lock, site activation, and every critical moment in between.

If you're running hybrid or decentralized studies and want televisit capability that doesn't require a separate integration, separate validation, or a separate vendor relationship, Viedoc is built for exactly that. Book a demo or request a proposal and our team will walk you through how Viedoc Televisits performs against your specific protocol requirements.